That is a stunning and very depressing comment.  

Ken


> On Sep 17, 2015, at 5:53 PM, Christopher Green <[email protected]> wrote:
> 
> 
> 
> 
> 
>  
> In the immortal words of Richard W. Smith, longtime editor of the British 
> Medical Journal, "Medical journals are an extension of the marketing arm of 
> pharmaceutical companies” (PLoS Med, 2005). 
> 
> It’s a pity that he kept that information to himself during the 25 years he 
> worked for the journal, only letting the cat out of the bag after he was out 
> the door. 
> 
> Chris
> …..
> Christopher D Green
> Department of Psychology
> York University
> Toronto, ON M3J 1P3
> Canada
> 43.773897°, -79.503667°
> 
> [email protected] <mailto:[email protected]>
> http://www.yorku.ca/christo <http://www.yorku.ca/christo>
> ………………………………...
> 
> On Sep 17, 2015, at 4:50 PM, Mike Palij <[email protected] <mailto:[email protected]>> 
> wrote:
> 
>> In 2001 the "Journal of the Academy of Child and Adolescent
>> Psychiatry" published a research study on the treatment of depression
>> in adolescents, randomized control trial (RCT) which had groups
>> that received paroxetine, imipramine, or placebo -- this study
>> is also known as "Study 329".  In that article it was claimed that
>> paroxetine was effective and safe to use with adolescents. At that
>> time there were those who questioned the research design and
>> the results but the marketing of paroxetine (by the company now
>> known as GlaxoSmithKline or GSK) made it widely used.
>> 
>> Critics of the Study 329 were able to get the original data and
>> documents and they completed and published a re-analysis of
>> the data which was just published in the British Medical Journal
>> or BMJ.  The main conclusion: one the primary measure of
>> depression, the three groups did not differ after 8 weeks of
>> treatment (i.e., paroxetine vs imipramine vs placebo).  No
>> effect at all.  However, the paroxetine group showed increased
>> suicidal ideation and behavior while the imipramine group showed
>> cardiovascular problems.  As you might imagine, all hell has
>> broken loose as a result.  The popular media has picked up
>> on this story and one source is (you guessed it) the New York
>> Times; see:
>> http://www.nytimes.com/2015/09/17/health/antidepressant-paxil-is-unsafe-for-teenagers-new-analysis-says.html?_r=0
>>  
>> <http://www.nytimes.com/2015/09/17/health/antidepressant-paxil-is-unsafe-for-teenagers-new-analysis-says.html?_r=0>
>> 
>> The re-analysis is available on the BMJ website; see:
>> http://www.bmj.com/content/351/bmj.h4320
>> 
>> The BMJ also has an editorial that highlights some of the research
>> and ethical problems associated with the research and those
>> who were involved in the origin study; see:
>> http://www.bmj.com/content/351/bmj.h4629
>> 
>> The title of the editorial is:
>> No correction, no retraction, no apology, no comment: paroxetine
>> trial reanalysis raises questions about institutional responsibility
>> 
>> I think this study beats Milgram and Zimbardo in the unethical department.
>> 
>> -Mike Palij
>> New York University
>> [email protected]
>> 
>> P.S. I find the following sentence from the editorial both frightening
>> and hilarious:
>> 
>> |The first draft of the manuscript ultimately published in the
>> |Journal of the American Academy of Child and Adolescent
>> |Psychiatry (JAACAP) was not written by any of the 22 named
>> |authors but by an outside medical writer hired by GSK. .
>> 
>> There were 22 authors and the paper was originally written
>> by a medical writer who probably didn't even get an authorship
>> credit.
>> 
>> 
>> ---
>> You are currently subscribed to tips as: [email protected].
>> To unsubscribe click here: 
>> http://fsulist.frostburg.edu/u?id=430248.781165b5ef80a3cd2b14721caf62bd92&n=T&l=tips&o=46811
>> or send a blank email to 
>> leave-46811-430248.781165b5ef80a3cd2b14721caf62b...@fsulist.frostburg.edu
> 
> ---
> 
> You are currently subscribed to tips as: [email protected] 
> <mailto:[email protected]>.
> 
> To unsubscribe click here: 
> http://fsulist.frostburg.edu/u?id=13524.94845a3ed9806f1cef14973830dd8c39&n=T&l=tips&o=46813
>  
> <http://fsulist.frostburg.edu/u?id=13524.94845a3ed9806f1cef14973830dd8c39&n=T&l=tips&o=46813>
> (It may be necessary to cut and paste the above URL if the line is broken)
> 
> or send a blank email to 
> leave-46813-13524.94845a3ed9806f1cef14973830dd8...@fsulist.frostburg.edu 
> <mailto:leave-46813-13524.94845a3ed9806f1cef14973830dd8...@fsulist.frostburg.edu>
> 
> 
> 
> 


---
You are currently subscribed to tips as: [email protected].
To unsubscribe click here: 
http://fsulist.frostburg.edu/u?id=13090.68da6e6e5325aa33287ff385b70df5d5&n=T&l=tips&o=46814
or send a blank email to 
leave-46814-13090.68da6e6e5325aa33287ff385b70df...@fsulist.frostburg.edu

Reply via email to